A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05789069 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma
Melanoma
Non Small Cell Lung Cancer
Gastric Cancer
Colorectal Cancer

Interventions

DRUG: HFB200603
DRUG: Tislelizumab

Sponsor

HiFiBiO Therapeutics